Indian biotech startup immunitoAI rakes in US$ 1 million in seed funding

ImmunitoAI, a Bengaluru, Karnataka-based AI-led biotech startup, has secured a fundraise of US$ 1 million (INR 7 Crore approx.) in seed funding round held yesterday, on September 08 2021. The early-stage venture capital fund Pi Ventures led the venture round. Biotech’s existing backer, Entrepreneur First, was also witnessed participating. 

ImmunitoAI will use the latest capital to expand its product development and industry partnerships, it said in an official statement. 

What the CEO has to say

Co-founder and CEO of immunitoAI, Aridni Shah, said, “Integration of AI with biology has become a reality today. Biology has always been difficult to study and understand, but with the use of AI, we have started to bridge the gaps, and what was thought to be impossible earlier has become possible. Our vision is to make antibody therapy a norm with the help of our technology. We plan on using this seed funding to develop our AI products and validate the predictions through biological experiments.”

What the Investor has to say

Managing Director at pi Ventures, Roopan Aulakh, remarked on the latest fundraising, “Our focus at pi has been to invest in startups that are revolutionizing industries using disruptive technology. This thesis is well reflected in immunitoAI, our first investment from our recently launched Fund II. The company’s AI-led platform will make the antibody discovery process faster and cheaper, enabling targeted therapy for multiple diseases. We are delighted to partner with Aridni and Trisha, who brings a unique combination of biotech and AI to the table.”

About immunitoAI

Aridni Shah co-founded ImmunitoAI (PhD in Biological Sciences from National Centre of Biological Sciences, TIFR) with Trisha Chatterjee (Masters in Computer Science with six years of R&D experience applying Artificial Intelligence and Machine Learning in various industries like Advertisement, Logistics, and more) in November 2020. ImmunitoAI is a life sciences (biotech) platform that leverages AI to revolutionize antibody discovery & therapeutics. It is an in-silico Antibody Discovery company that uses Artificial Intelligence to give you the fastest and most accurate solutions. Product-base offered by the female-founded startup include, 

• Imran – Screen and Rank Antibodies– imRANK is an AI that screens and ranks existing antibody sequences to predict the best binding strength with a given antigen of your choice
• imEVOLVE – Evolve Antibodies- imEVOLVE is an AI that identifies and mutates regions of antibodies that aids in higher binding affinity with the antigen of your choice. 

For more information about their products, check out https://www.immunitoai.com/products.

For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.

We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!

Next Article